Abstract
Objective: Alefacept is a biologic treatment for psoriasis, with a selective effect on memory effector T cells. Few data are available on the combination of alefacept with either topical or systemic anti‐psoriatics. We studied the effect of alefacept combination treatment on clinical disease severity scores and on circulating T‐cell subsets. Methods: Twelve patients with moderate‐to‐severe psoriasis were included and treated with alefacept for a period of 12 weeks. Patients were allowed to continue the anti‐psoriatic therapies they used prior to the study. Severity of disease and expression of T‐cell markers CD4, CD8, CD45RA, CD45RO, CD94, CD161, CD25, and CLA were assessed at baseline and after treatment. Results: Seven of 12 included patients used a concomitant systemic therapy: either methotrexate (n = 4), acitretin (n = 2) or cyclosporine (n = 1). PASI reductions in this group after 12 and 24 weeks were 40% and 55%, respectively. Several lymphocyte subsets showed a reduction in circulating numbers. These decreases were independent of the use of an additional systemic psoriasis therapy. Conclusions: The concomitant use of systemic anti‐psoriatic medication in combination with alefacept has a noteworthy impact on efficacy results. No differences in circulating psoriasis‐relevant T‐cell populations between patients with or without an additional systemic treatment were seen.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
